CARLSBAD, Calif. — Glanbia Nutritionals, Inc., a global ingredient solutions and nutritional premix provider, announced today an agreement with Norway based NattoPharma ASA, a worldwide innovator and pioneer of Vitamin K2 for distribution in the United States and Canada of their MenaQ7® PURE, a nature-identical synthetic vitamin K2 as menaquinone-7 (MK-7) ̶ the first-in-class, only clinically researched Vitamin K2.
Supported by a global IP portfolio and revolutionary research substantiating clear efficacy for bone and cardiovascular health, MenaQ7®PURE helps the body to inhibit and “clean up” calcium in the arteries while promoting arterial flexibility and is the optimal solution to utilize calcium in the body by binding calcium to the bones. A 3-year study on 244 healthy women taking MenaQ7®showed statistically significant protection of the vertebrae and the hip (femoral neck) from bone loss.
“We are excited for the addition of MenaQ7®PURE to our ingredients portfolio,” said Ram Nimmagudda, Director of Business Development for Glanbia Nutritionals. “Its ability to promote both bone and arterial health will help to diversify our proprietary ingredient portfolio further, providing our customers with additional ingredient solutions to meet their health platform needs.”
NattoPharma’s MenaQ7®PURE is produced in a European pharmaceutical manufacturing facility and is fully validated by numerous human clinical studies, as well as in-vivo and in-vitro research; it is recognized by the world’s leading experts in research and development of vitamin K2 at University of Maastricht (Netherlands) for exceptional purity and quality. A patent-pending synthesis process produces a uniquely pure vitamin K2 molecule that provides a much more desirable outcome for stability, efficacy, and safety.
Glanbia Nutritionals offers the premier portfolio of innovative, clinically-driven specialty ingredient solutions. Combined with our extensive expertise in custom premix, Glanbia Nutritionals is a complete fortification partner uniquely positioned to support the needs of fast-moving nutrition companies.
About Glanbia Nutritionals, Inc.
Glanbia Nutritionals is a global leader in ingredient solutions, providing customized premixes, amino acids, vitamins, minerals, specialty ingredients and colors for the food, beverage and supplement industries.
Glanbia Nutritionals is a division of Glanbia plc which operates in 32 countries worldwide and employs 5,200 people globally. As a global performance nutrition and ingredients group, Glanbia holds the leading market positions in cheese, dairy ingredients including whey and other protein isolates, specialty non-dairy ingredients and is the number one global brand leader in sports nutrition.
Glanbia is listed on both the Irish and London Stock Exchange (GLB).
NattoPharma USA, Inc. is the wholly owned U.S. subsidiary of NattoPharma ASA, Norway, which is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7®, the natural vitamin K2 as MK-7, and the company has been in a multi-year research and development program to substantiate and discover the health benefits of natural vitamin K2 for applications in the marketplace for functional food and dietary supplements. For more information, visit nattopharma.com.